Array BioPharma (NASDAQ:ARRY) reported Q2 2018 earnings this Morning, coming in at ($0.17) per share, beating Wall Street’s estimates of ($0.23) per Share. Revenue for the quarter came in at $42.21 million beating analyst estimates of $26.81 million Recent Insider Trading for Array BioPharma (NASDAQ:ARRY)
- On 1/17/2018 Lunsen Gil J Van, Director, sold 21,500 with an average share price of $12.94 per share and the total transaction amounting to $278,210.00.
- On 1/16/2018 Jason Haddock, CFO, sold 7,500 with an average share price of $13.73 per share and the total transaction amounting to $102,975.00.
- On 12/19/2017 Ron Squarer, CEO, sold 819,671 with an average share price of $10.86 per share and the total transaction amounting to $8,901,627.06.
- On 12/18/2017 Andrew R. Robbins, COO, sold 282,874 with an average share price of $10.72 per share and the total transaction amounting to $3,032,409.28.
- On 9/29/2017 Kyle Lefkoff, Director, sold 38,865 with an average share price of $12.31 per share and the total transaction amounting to $478,428.15.
- On 3/28/2017 Charles M Baum, Director, sold 25,000 with an average share price of $9.27 per share and the total transaction amounting to $231,750.00.
Recent Trading for Array BioPharma (NASDAQ:ARRY) Shares of Array BioPharma closed the previous trading session at 14.32 up +0.23 1.63% with 14.539999961853027 shares trading hands.